PROTACs
PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.
PROTACs Isoform Specific Products
All Product Categories
-
PROTACs Related Products (1334)
Related Products (1334)
-
Antibodies (1)
-
PROTACs Isoform Comparison
-
RPG-01-132
0 ImagesCat. No.: HY-181920RPG-01-132 is a DENV capsid protein PROTAC degrader, with a DC50 of 2.4 μM. RPG-01-132 blocks viral assembly, eliminates viral particles, and interferes with the non-structural functions of capsid protein. RPG-01-132 exhibits significant antiviral activity against all four DENV serotypes and the ST148 (HY-121663)-resistant DENV2 mutant strain. RPG-01-132 is applicable to research related to dengue virus infection.
-
MZ 1 (Standard)
0 ImagesCat. No.: HY-107425RCAS No.: 1797406-69-9MZ 1 (Standard) is the analytical standard of MZ 1 (HY-107425). This product is intended for research and analytical applications. MZ 1 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4 over BRD2 and BRD3. Kds of 382/120, 119/115, and 307/228 nM for BRD4 BD1/2, BRD3 BD1/2, and BRD2 BD1/2, respectively.
-
Jun15702
0 ImagesCat. No.: HY-182924Jun15702 is a PROTAC degrader targeting the capsid protein VP1 of enterovirus D68. Jun15702 recruits the Cereblon (CRBN) E3 ligase and activates the ubiquitin-proteasome pathway. Jun15702 inhibits viral entry and exerts inhibitory effects during the early, middle and late stages of viral replication. Jun15702 exhibits antiviral activity against multiple wild-type enterovirus D68 strains, and also shows submicromolar antiviral activity against the Pleconaril (HY-19952)-resistant enterovirus D68 variant rMO-VP1 F159V. Jun15702 can be used in studies related to enterovirus D68 (EV-D68) infection.
-
PROTAC CG167
0 ImagesCat. No.: HY-173009PROTAC CG167 is a selective and potent CypA PROTAC degrader. PROTAC CG167 degrades CypA in a dose-dependent manner (Jurkat: DC50: 123 nM). PROTAC CG167 can inhibit HIV-1 and HCV and exhibits antiviral activity. (Pink: CypA Ligand (HY-170997); Black: Linker (HY-W123015); Blue: E3 Ligase Ligand (HY-112078))
-
PROTAC SARS-CoV-2 Mpro degrader-5
0 ImagesCat. No.: HY-181154PROTAC SARS-CoV-2 Mpro degrader-5 is a SARS-CoV-2 main protease (Mpro) PROTAC. PROTAC SARS-CoV-2 Mpro degrader-5 engages CRBN E3 ubiquitin ligase to form a ternary complex with SARS-CoV-2 Mpro, induces K48-linked polyubiquitination of SARS-CoV-2 Mpro, and drives proteasome-dependent turnover of SARS-CoV-2 Mpro with a high selectivity index (CC50/DC50 > 10) in human embryonic kidney cells.PROTAC SARS-CoV-2 Mpro degrader-5 can be used for the research of COVID-19.
-
PROTAC CDK9 Degrader-1 (Standard)
0 ImagesCat. No.: HY-103628RCAS No.: 2118356-96-8
-
dBET1 (Standard)
0 ImagesdBET1 (Standard) is the analytical standard of dBET1 (HY-101838). This product is intended for research and analytical applications. dBET1 is a PROTAC connected by ligands for Cereblon and BRD4 with an EC50 of 430 nM. dBET1 is a PROTAC that composes of (+)-JQ1 (HY-13030) linked to NSC 527179 (HY-14658) with a linker.
-
PROTAC BET Degrader-1 (Standard)
0 ImagesCat. No.: HY-103633RCAS No.: 2093386-22-0PROTAC BET Degrader-1 (Standard) is the analytical standard of PROTAC BET Degrader-1 (HY-103633). This product is intended for research and analytical applications. PROTAC BET Degrader-1 is a BRD2/BRD3/BRD4 PROTAC degrader. PROTAC BET Degrader-1 inhibits the growth of acute leukemia cells. PROTAC BET Degrader-1 is applicable to the research of acute leukemia.
-
PROTAC HBeAg degrader-1
0 ImagesCat. No.: HY-174856PROTAC HBeAg degrader-1 is a PROTAC targeting degradation agent for HBeAg. PROTAC HBeAg degrader-1 recruits the VHL E3 ligase but degrades HBV protein HBeAg through VHL-independent mechanism. PROTAC HBeAg degrader-1 decreases levels of secreted and intracellular HBeAg. PROTAC HBeAg degrader-1 can be used for the research of hepatitis B virus (HBV).
-
ZXH-8-004
0 ImagesCat. No.: HY-161806ZXH-8-004 is a DENV E PROTAC degrader with a DC50 value of 0.21 µM in Huh7.5 cells. ZXH-8-004 induces CRBN- and proteasome-dependent degradation of intracellular dengue virus envelope protein. ZXH-8-004 inhibits envelope-mediated membrane fusion during viral entry and reduces the production of infectious dengue virus particles. ZXH-8-004 can be used in studies related to dengue virus infection, Zika virus infection, Japanese encephalitis virus infection, West Nile virus infection, and yellow fever virus infection.
-
ZBP1 PROTAC-1
0 ImagesCat. No.: HY-185102ZBP1 PROTAC-1 is a Z-DNA-binding protein 1 (ZBP1) PROTAC degrader with a DC50 of 25.69 nM. ZBP1 PROTAC-1 consists of a DNA aptamer that specifically binds to ZBP1 and an E3 enzyme-recruiting moiety. ZBP1 PROTAC-1 combines the specificity and covalent binding ability of DNA aptamers with the PROTAC-mediated degradation function. By degrading ZBP1, ZBP1 PROTAC-1 inhibits the phosphorylation of RIPK3/MLKL to necrotic apoptosis and reduces the levels of proinflammatory cytokines (IL-18, IL-1β, IL-6, TNF-α, IFN-β). ZBP1 PROTAC-1 can be used in the research of viral pneumonia and influenza A H1N1 virus infection.
-
PROTAC BRD4 Degrader-49
0 ImagesCat. No.: HY-185854CAS No.: 3115940-40-1BRD4 degrader-8 is a BRD4-targeting degrader. BRD4 degrader-8 induces degradation of BRD4 protein via the ubiquitin-proteasome pathway. BRD4 degrader-8 can be used for the research of hematologic tumors, gastrointestinal stromal tumors, histiocytic lymphoma, non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell carcinoma, colorectal cancer, kidney cancer, gastric cancer, head and neck cancer, nasopharyngeal cancer.
